Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
Phase 4
2005-10-01
This is an efficacy and safety study of Vytorin (ezetimibe (+) simvastatin) compared to
atorvastatin (ezetimibe/simvastatin) at week 6 in primary hypercholesterolemia patients in
Korea. The primary hypothesis being tested is that daily administration of Vytorin will
result in a greater reduction of low density lipoprotein cholesterol (LDL-C) concentration
from baseline after 6 weeks treatment compared to atorvastatin.
IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2005-10-17
This is a randomized, active-control, double-blind study of subjects with stabilized
high-risk acute coronary syndrome (ACS). The primary objective is to evaluate the clinical
benefit of Ezetimibe/Simvastatin Combination 10/40 (single tablet, under the brand VYTORIN in
the United States) compared with Simvastatin 40 mg. As per the original protocol, if
low-density lipoprotein cholesterol (LDL-C) response was inadequate, the dose of simvastatin
in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011
protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new
increases of simvastatin dose to 80 mg were stopped). Clinical benefit will be defined as the
reduction in the risk of the occurrence of the composite endpoint of cardiovascular (CV)
death, major coronary events, and stroke.
Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)
Terminated
Merck Sharp & Dohme Corp.
Phase 3
2006-09-01
To compare the effectiveness of ezetimibe/simvastatin 10/40 daily to atorvastatin 80 daily in
reducing the concentration of ldl-c at endpoint after 6 weeks of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
